Vasomune Therapeutics completed enrollment in a randomized Phase 2a trial evaluating pegevongitide (AV-001) in patients hospitalized with pneumonia requiring supplemental oxygen. The company is running AV001-004 as a double-blind, placebo-controlled study and said enrollment completion advances the FDA Fast Track-designated program toward data review. Vasomune described pegevongitide as a Tie2 receptor activator designed to reinforce the endothelial barrier and correct pulmonary vascular response associated with vascular leak and impaired oxygen exchange. Following enrollment completion, the company said it will move into data quality assurance, site closeout, and preparation for database lock. FDA Fast Track designation is intended to expedite development and review for therapies addressing serious conditions with unmet medical need, and the Phase 2a milestone brings Vasomune closer to reporting clinical outcomes.